CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population

Indian Journal of Dermatology

Volumn 55, Issue 1, 2010, Pages 29-32

  Deeba, Farha ^a   Syed, Rabbani ^b   Quareen, Jariya ^c   Waheed, M ^c   Jamil, Kaiser ^b   Rao, Hanmanth ^a  

^a OSMANIA UNIVERSITY   (India)

^b Hyderabad and School of Biotechnology   (India)

^c Central Research Institute of Unani Medicine   (India)

Author keywords

Autoimmune; CTLA 4; Melanocytes; Polymorphism; Vitiligo

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNITY; CHI SQUARE TEST; CHILD; CHROMOSOME 2Q; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; EXON; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; VITILIGO;

EID: 77949555689     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.60347     Document Type: Article

References (32)

1. Mollet I, Ongenae K, Naeyaert JM. Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders. Dermatol Clin 2007;25:363-371
2. Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 2008;10:227-243
3. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients, J Dermatol 1999;10:653-657
4. Groysmane V, Sami N. Vitiligo e-medicine, dermatology, Disease of pigmentation Aug 2008.
5. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-666
6. Halder R, Taliaferro S. Vitiligo. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, eds. Fitzpatrick's Dermatology in General Medicine. Vol.1. 7th ed. 2008. p. 72.
7. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci 2005;39:137-146
8. Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008;10:244-257
9. Shajil EM, Chatterjee S, Agrawal D, Bagchi T, Begum R. Vitiligo: Pathomechanisms and genetic polymorphism of susceptibility genes, Indian J Exp Biol 2006;44:526-539
10. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Expert Rev Mol Med 2001;3:1-22.
11. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413
12. Fattahi MJ, Pezeshki AM. Lack of Association between CTLA-4 A49G Polymorphism and Vitiligo IJI Vol. 2 No.2 Spring 2005.
13. Kalantari T, Mostafavi H, Pezeshki AM, Farjadian S, Doroudchi M, Yeganeh F, et al. Exon-1 polymorphism of CTLA- 4 gene in Iranian patients with Graves' disease. Autoimmunity 2003;36:313-316
14. Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997;82:4130-4132
15. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nuñez-Roldan A. CTLA-4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 1999;53:296-300.
16. Kemp EH, Ajjan RA, Waterman EA, Gawkrodger DJ, Cork MJ, Watson PF, et al. Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo. Br J Dermatol 1999;140:73-78
17. Kikuoka N, Sugihara S, Yanagawa T, Ikezaki A, Kim HS, Matsuoka H, et al. Cytotoxic T lymphocyte antigen 4 gene polymorphism confers susceptibility to type 1 diabetes in Japanese children: analysis of association with HLA genotypes and autoantibodies. Clin Endocrinol (Oxf) 2001;55:597-603.
18. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100.
19. Bystryn JC. Theories on the pathogenesis of depigmentation: Immune hypothesis. In: Hann SK, Nordlund JJ, editors. Vitiligo. Oxford: Blackwell Science; 2000. p. 129-136
20. van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001;81:1061-1067
21. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 2001;22:130-136
22. Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-332
23. Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170:149-155
24. Le Poole IC, van den Wijngaard RM, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation. J Invest Dermatol 1993;100:816-822
25. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol 1997;137:171-178
26. Vitiligo DJ. In: La pratique dermatologique. Vol.4. Paris: Masson; 1904. p. 846-858
27. Shevach EM. Certified professionals: CD4(1)CD25(1) suppressor T cells. J Exp Med 2001;193:F41-6.
28. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(1)CD4(1) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
29. Suto A, Nakajima H, Ikeda K, Kubo S, Nakayama T, Taniguchi M, et al. CD4(1)CD25(1) T-cell development is regulated by at least 2 distinct mechanisms. Blood 2002;99:555-560
30. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-6611
31. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003;31:21-36.
32. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases-A general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-184